**Insist on Better AML Care**

- Ensure you have undergone biomarker testing prior to choosing treatment.
- Consider a second opinion and/or a consult with a lung cancer specialist.
- Include a friend or family member in your appointments.
- Always speak up and ask questions. You have a voice in YOUR care.

### Common AML Mutations

**IDH (Isocitrate Dehydrogenase) Mutations:** Mutations in IDH1 or IDH2 are detected in approximately 20 percent of patients with AML.

**FLT3 Mutation:** FLT3 stands for Fms-like tyrosine kinase. This gene mutation occurs in approximately 30 percent of AML patients.

**NPM1 (Nucleophosmin-1) Mutation:** The most common molecular mutation identified in adult AML.

**TP53 (tumor protein 53) Mutation:** A gene that helps stop the growth of tumors. TP53 is the most frequently mutated gene in human tumors. TP53 mutation rates are low in AML.

### Approved FLT3 Inhibitors

- Midostaurin (Rydapt)
- Gilteritinib (Xospata)
- Sorafenib (Nexavar)

### Approved IDH Inhibitors

- Enasidenib (Idhifa)
- Ivosidenib (Tibsovo)

### AML Resources and Support

- CancerGrace
- Cancer Support Community
- Know AML

- National Organization for Rare Disorders (NORD)
- The Leukemia & Lymphoma Society (LLS)

### Glossary Terms

**Aspirate:** Withdrawing fluid, tissue, or other substance from the body for further examination of a disease or condition.

**Bone Marrow Biopsy:** Procedure that involves collecting a small sample of bone marrow, usually from the hip bone, in order to be examined by a laboratory. This procedure is used to confirm a diagnosis and may be used to monitor the disease over time.

**Biomarker Testing (molecular testing):** Laboratory testing that identifies certain genes, proteins, or other molecules in a sample of tissue, blood, or other body fluid. In cancer, it may also be used to evaluate treatment or to make a prognosis.

**Molecular Testing (genetic or biomarker testing):** Laboratory testing that identifies certain gene mutations, proteins, chromosomal abnormalities and/or other molecular changes that are unique to an individual’s disease. In cancer, it may be used to evaluate treatment or to make a prognosis.

**Menin Inhibitors:** Type of therapy being studied in patients with AML that have the NPM1 mutation or the MLL rearrangement chromosome.

**Targeted Therapy:** A type of personalized medicine that works by blocking specific mutations and by preventing cancer cells from growing and dividing, without affecting normal cells.

---

Insist! AML is brought to you by the Patient Empowerment Network. It is made possible through support from Bristol Myers Squibb, Foundation Medicine, and generous donations from people like you.

© 2022 Patient Empowerment Network, a 501(c)(3) Public Charity

www.powerfulpatients.org